LSX’s Inv€$tival Showcase – Nov 08-15
Orion will be presenting a video at the LSX’s Inv€$tival Showcase which is being held as a hybrid event with both online and in-person meetings. We are looking forward to
Unlocking the Therapeutic Potential of Complex GPCRs
Orion Biotechnology is a clinical stage company discovering and developing next-generation G Protein-Coupled Receptor (GPCR)-targeted therapeutics for the treatment of cancer and other serious diseases.
Orion’s novel drug modality involves precision engineering ligands of peptide and protein GPCRs to develop analogs with significant advantages over small molecule and antibody approaches
CCR5 Inhibitor Program
Orion’s lead compound, OB-002, is a GPCR analog of CCL5 with best-in-class potency and a proven mechanism of action shown to have broad applicability across a range of serious diseases, including Cancer, Infectious Disease and Neuroinflammatory disorders.
Recognized
Leadership
Previous
Next
Jefferies London Healthcare Conference – Nov 16 -19
Members of Orion’s management team will be participating in this year’s conference. The Jefferies London Healthcare conference, will be another hybrid event, with In-Person meetings on Tuesday and Wednesday, followed
Orion Receives Funding to Advance its Lead GPCR-Targeted Therapeutic
November 14, 2021
Ottawa, Canada [November, 04 2021]: Orion Biotechnology Canada Ltd., a clinical stage company unlocking the therapeutic potential of G Protein-Coupled Receptors (GPCRs) with a novel drug modality, proven discovery platform
Orion Adds Industry Leader to Board
September 1, 2021
Ottawa, Canada, Aug. 31, 2021 (GLOBE NEWSWIRE) — Orion Biotechnology, a clinical stage company that is developing novel G Protein-Coupled Receptor (GPCR)-targeted therapeutics for the treatment of cancer and other
Orion Biotechnology Secures $11.5M Series A Financing
June 18, 2021
Ottawa, Canada [June 17, 2021]: Orion Biotechnology Canada Ltd., a clinical-stage biotechnology company, today announced that it has raised $11.5M USD in a Series A financing. The oversubscribed round was led
Global Headquarters
343 Preston Street
11th floor,
Ottawa, On K1S 1N4
CANADA
+1 343.291.1032
Switzerland
Campus Biotech
Innovation Park
Avenue de Sécheron 15
1202 Genève
SWITZERLAND
Poland
Orion Biotechnology
Life Science Park
UI Bobrzyńskiego 14
30-348 Krakôw
POLAND
